Overview
Methylene blue (methylthioninium chloride) is a synthetic phenothiazine dye first synthesized in 1876 and one of the oldest drugs in continuous clinical use. It is FDA-approved for the treatment of acquired methemoglobinemia, in which iron in hemoglobin is oxidized to the ferric (Fe³⁺) state and loses oxygen-carrying capacity. Methylene blue reduces methemoglobin back to functional hemoglobin via the NADPH-dependent methemoglobin reductase pathway.
Beyond its approved indication, methylene blue has a wide range of investigational uses. At low doses (typically 0.5–4 mg/kg orally) it acts as an alternative mitochondrial electron carrier, bypassing dysfunctional segments of the electron transport chain and increasing cellular ATP production. This mechanism has motivated research into its potential utility for neurodegenerative disease, ischemic injury, cognitive dysfunction, and mitochondrial myopathies.
Methylene blue also inhibits monoamine oxidase A (MAO-A) and nitric oxide synthase, and at higher concentrations it inhibits acetylcholinesterase. The MAO-A inhibition underlies its most important drug-interaction warning: combination with serotonergic agents (SSRIs, SNRIs, MAOIs, triptans, tramadol) can precipitate serotonin syndrome, sometimes severe.
Methylene blue is widely available, inexpensive, and used by clinicians for an expanding list of off-label indications including vasoplegic shock, ifosfamide-induced encephalopathy, and intraoperative parathyroid localization. Pharmaceutical-grade product (USP) should be used for any human use; industrial-grade methylene blue may contain heavy-metal and other contaminants.
Quick facts
- Mechanism
- Phenothiazine redox cycler acting as alternative mitochondrial electron carrier and methemoglobin reductant
- Primary use
- Methemoglobinemia treatment; cognition, mitochondrial, and neuroprotection research
- Evidence
- moderate
- FDA
- Approved
- Route
- Intravenous (clinical) or oral (off-label, low dose)
- Typical results
- Methemoglobinemia reversal within 30–60 minutes at therapeutic IV doses; cognitive and mitochondrial effects suggested at low oral doses (~0.5–4 mg/kg) over weeks
Chemical information
Methylene Blue (C₁₆H₁₈ClN₃S) is a metabolic compound with a molecular weight of 319.9 g/mol. Its structural characteristics underpin its biological activity in metabolic regulation and energy homeostasis.
How Methylene Blue works
Methylene blue is a redox-active molecule that cycles between its oxidized form (blue, MB⁺) and reduced form (colorless, leucomethylene blue, MBH). It accepts electrons from NADPH via cytosolic methemoglobin reductase, then transfers them to methemoglobin, restoring functional hemoglobin. In mitochondria, methylene blue can accept electrons from NADH and donate them to cytochrome c, bypassing complexes I and III when these are inhibited or damaged—an effect that maintains oxidative phosphorylation under stress.
At low concentrations (nanomolar to low micromolar), methylene blue augments mitochondrial respiration, increases cytochrome oxidase activity, and reduces oxidative stress. At higher concentrations (>10 µM) it behaves as a pro-oxidant, generating reactive oxygen species and inhibiting respiration—a biphasic hormetic dose-response that explains why low oral doses are typically used in neuroprotective and cognitive research.
Additional pharmacology includes potent reversible inhibition of MAO-A (the principal serotonin-metabolizing enzyme), reversible inhibition of soluble guanylate cyclase (limiting NO-driven vasodilation, hence its use in vasoplegic shock), and inhibition of tau protein aggregation in preclinical Alzheimer's models. A leucomethylene blue derivative (hydromethylthionine, LMTM/TRx0237) advanced to Phase 3 for Alzheimer's disease but did not meet its primary endpoint.
Methylene blue crosses the blood-brain barrier and concentrates in mitochondria-rich tissues including brain, heart, and muscle. Plasma half-life is ~5–6 hours with the parent compound predominantly excreted in urine as a mixture of methylene blue and its reduced metabolite, often producing visible blue or green discoloration.
- Methemoglobin reduction: Restores Fe²⁺ hemoglobin via NADPH-methemoglobin reductase pathway
- Mitochondrial electron shuttle: Bypasses damaged complexes I/III, sustaining ATP under stress
- Hormetic dose-response: Antioxidant at low doses, pro-oxidant at high doses
- MAO-A inhibition: Primary basis for serotonin-syndrome drug interactions
- Guanylate cyclase inhibition: Mechanism behind use in refractory vasoplegic shock
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Molecular Mass | 319.9 g/mol | Small lipophilic molecule |
| Oral bioavailability | ~70% | Adequate for low-dose oral protocols |
| Tmax (oral) | 1–2 hours | Onset relevant for cognitive dosing |
| Half-life | ~5–6 hours | Permits 1–2 daily oral doses |
| Distribution | Wide; crosses BBB; concentrates in mitochondria-rich tissues | Underpins CNS, cardiac, and muscle effects |
| Elimination | Urine and bile (often visibly blue/green) | Patients should be warned about discoloration |
Dosing & administration
Methylene Blue dosing varies by indication and individual factors. Refer to the official prescribing information for approved indications.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Side effects & safety
Safety data for Methylene Blue is established for approved indications via clinical trials. Long-term effects in humans remain incompletely characterized.
Common
- • Blue/green discoloration of urine, saliva, and tongue
- • Mild nausea and dyspepsia
- • Headache
- • Dizziness
- • Sweating
Serious / potential risks
- • Serotonin syndrome when combined with serotonergic drugs
- • Hemolytic anemia in G6PD deficiency
- • Methemoglobinemia at high doses (paradoxical effect)
- • Hypertension and arrhythmia (high IV doses)
- • Hypersensitivity reactions
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| SSRIs/SNRIs/MAOIs/triptans/tramadol | Serotonin syndrome risk (FDA warning) | Avoid combination; if MB needed in emergency, discontinue serotonergic agent if possible |
| G6PD-deficient patients | Hemolytic anemia risk | Screen for G6PD deficiency before non-emergency use |
| Nitrate vasodilators | MB inhibits NO-cGMP signaling, blunting vasodilation | Use caution in patients dependent on nitrate therapy |
| Iron supplements | Potential interference with hematology assessment | Separate dosing; routine clinical monitoring |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
Methylene Blue is a metabolic compound with research interest in mitochondrial support, cognition, anti-aging, neuroprotection. While preclinical evidence is encouraging, it has received FDA approval for specific indications. Any use should be under qualified medical supervision.
Best for
- • Researchers studying metabolic regulation and energy homeostasis
- • Individuals interested in mitochondrial support under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
NAD+
Complementary mitochondrial cofactor supporting electron transport
SS-31
Mitochondria-targeted peptide protecting cardiolipin and ETC function
Glutathione
Major endogenous antioxidant complementing MB redox effects
Humanin
Mitochondrial-derived peptide with neuroprotective overlap
Frequently asked questions
References
- [1] Wainwright M, Crossley KB.. Methylene blue—a therapeutic dye for all seasons?. J Chemother (2002). doi: 10.1179/joc.2002.14.5.431 PMID: 12462423
- [2] Rojas JC, Bruchey AK, Gonzalez-Lima F.. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol (2012). doi: 10.1016/j.pneurobio.2011.10.007 PMID: 22067440
- [3] Gauthier S, Feldman HH, Schneider LS, et al.. Efficacy and safety of tau-aggregation inhibitor LMTM in mild to moderate Alzheimer's disease. Lancet (2016). doi: 10.1016/S0140-6736(16)31275-2 PMID: 27863809
- [4] Ramsay RR, Dunford C, Gillman PK.. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A explains a serotonin toxicity reaction. Br J Pharmacol (2007). doi: 10.1038/sj.bjp.0707253 PMID: 17486138